Zuckerberg San Francisco General Hospital
San Francisco, California, 94110, United States
Location status: Recruiting
Location contact
Edilberto Amorim, MD
CONTACT
NCT Number: NCT06401707
Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 2
San Francisco, California, 94110, United States
Location status: Recruiting
Edilberto Amorim, MD
CONTACT
More than 500,000 Americans have a cardiac arrest every year and 100,000 survive to hospital admission. Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. Seizures with or without muscle jerks, i.e. myoclonic seizures, are the most common seizure type after a cardiac arrest. Despite being common, seizures are usually refractory to treatment (post-cardiac arrest refractory status epilepticus) and the vast majority of patients with this diagnosis die. We are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for PCARSE prevention after cardiac arrest. Perampanel is a non-competitive AMPA glutamate receptor antagonist approved for adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures, however there are no randomized trials in critically ill cardiac arrest patients at risk for seizures. This medication has been used for the management of refractory status epilepticus, including status epilepticus post-cardiac arrest. We will randomize patients to placebo or perampanel after admission to the intensive care unit. The study's primary outcome will be the incidence of severe adverse events. Secondary efficacy and safety endpoints include incidence of seizures and PCARSE, seizure frequency, time to seizure control, number of anti-seizure medications necessary for seizure control, duration of treatment with anesthetics for seizure control, and time to coma awakening. This study will help determine the safety and feasibility of primary seizure prophylaxis after cardiac arrest.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Perampanel is a non-competitive AMPA glutamate receptor antagonist.
Other names: Fycompa
Placebo
Time frame: 7 days
percentage of participants who are able to complete the 5-day course of perampanel or placebo.
Time frame: 7 days
percentage of participants with treatment-related adverse and serious adverse events in perampanel or placebo arms.
Time frame: 7 days
percentage of participants with post-cardiac arrest refractory status epilepticus in perampanel or placebo arms.
Time frame: 7 days
percentage of participants with post-cardiac arrest seizures in perampanel or placebo arms.
Time frame: 7 days
number of anti-seizure medications and anesthetics needed for post-cardiac arrest status epilepticus control in perampanel or placebo arms.
Time frame: 7 days
percentage of participants with post-cardiac arrest refractory status epilepticus in perampanel or placebo arms.
Time frame: 180 days
Distribution of modified Rankin Scale (mRS) score at 180 days in perampanel or placebo arms (mRS range 0 to 6, with higher scores indicating worse outcome)
Contact information is provided by the study sponsor or research team.
University of California, San Francisco
Other
Acronym: PROSPER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05851391
Anoxia-Ischemia, Cerebral, Anoxic-Ischemic Encephalopathy
San Francisco, California, United States
View Trial DetailsNCT02458820
Cardiovascular Diseases, Heart Arrest
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT02486211
Anoxia, Body Temperature Changes
Portland, Maine, United States
View Trial DetailsNCT03544489
Behavior, Cardiovascular Diseases
Seattle, Washington, United States
View Trial Details